LB Pharmaceuticals entered into agreements for a private placement expected to raise approximately $150 million, selling 3,577,560 common shares at $34.94 and issuing pre-funded warrants for 715,513 shares at $34.9399. Proceeds will support expansion of LB-102 into additional indications, including potential trials for negative symptoms of schizophrenia and Alzheimer’s disease agitation/psychosis, and general corporate purposes. The company also granted registration rights to investors, committing to file a resale registration statement within 90 days of closing and maintain effectiveness until the securities are sold or freely tradable under Rule 144.
Agreement 1: LB Pharmaceuticals to Raise ~$150 Million in Private Placement at $34.94 Per Share
- Agreement type: Securities Purchase Agreement for private placement of common stock and pre-funded warrants
- Counterparty: Certain Investors
- Signed / Effective: Jul 28 2026 / same
- Duration / Termination: At will
- Reason: Fund LB-102 expansion and general corporate purposes
Agreement 2: LB Pharmaceuticals Grants Investors Registration Rights for Resale of New Shares
- Agreement type: Registration Rights Agreement for resale of shares and warrant shares
- Counterparty: Certain Investors
- Signed / Effective: Jul 28 2026 / same
- Duration / Termination: Until resale completed or Rule 144 eligible
- Reason: Provide liquidity to investors from the private placement
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.